Abstract Number: 1765 • ACR Convergence 2021
Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG A and/or Two BILAG B Domain Scores?
Background/Purpose: High placebo response rates have challenged interpretation of clinical trial results in SLE and may have contributed to failure of some effective treatments. One…Abstract Number: 1664 • 2017 ACR/ARHP Annual Meeting
Serum FAS, Ferritin, Igfbp2, sTNFR2 As Markers for Tracking Mucocutaneous and Musculoskeletal Flares in SLE Patients
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multi-systemic autoimmune disease, with a broad spectrum of clinical manifestations and unpredictable disease course with periods of…Abstract Number: 1986 • 2017 ACR/ARHP Annual Meeting
Using the BILAG to Assess the Activity of Lupus in Patients with Fibromyalgia
Background/Purpose: The BILAG is often used to assess the efficacy of lupus treatments, and is a commonly used tool in lupus drug trials. But the…Abstract Number: 2602 • 2017 ACR/ARHP Annual Meeting
Identification of Clinical and Serological Predictive Factors of Response to Rituximab Treatment in Systemic LUPUS Erythematosus (SLE) Patients
Background/Purpose: Response to Rituximab (RTX) varies significantly between Systemic Lupus Erythematosus (SLE) patients. Ethnicity may play a role in these differences, and a possible relationship…Abstract Number: 4L • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
Background/Purpose: In phase 2b trials, epratuzumab, a humanized anti-CD22 mAb that modulates B cell signaling without total B cell depletion, significantly improved disease activity in…Abstract Number: 1837 • 2015 ACR/ARHP Annual Meeting
Predictability of Musculoskeletal Flares and Hand Deformities in Systemic Lupus Erythematosus By High Resolution Ultrasound : 5-Year Clinical and Imaging Prospective Follow-up Study
Background/Purpose: SLE patients develop non-deforming non-erosive (NDNE) arthritis in 70-80%, but 5-15% of cases progresses into Jaccoud's arthropathy (JA) a non-erosive deforming arthritis. This study…Abstract Number: 2834 • 2014 ACR/ARHP Annual Meeting
Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open-Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus
Background/Purpose Epratuzumab is a monoclonal antibody in development for the treatment of systemic lupus erythematosus (SLE) that binds CD22, promoting the natural inhibitory function of…Abstract Number: 676 • 2014 ACR/ARHP Annual Meeting
Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
Background/Purpose: Published efficacy data for rituximab in SLE are complex with positive single-centre case series and negative randomised controlled trials. This may be due to…Abstract Number: 2531 • 2013 ACR/ARHP Annual Meeting
Elevated Combined Serum Free Light Chains Are Associated With Active Disease In Systemic Lupus Erythematosus
Background/Purpose: Chronic and hyper-stimulated B cells are characteristics commonly found in patients with systemic lupus erythematosus (SLE). Due to the complexity and variability observed during…Abstract Number: 1738 • 2013 ACR/ARHP Annual Meeting
Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study
Background/Purpose: Epratuzumab is a monoclonal antibody targeting CD22. In EMBLEMTM (dose-ranging phase IIb study), epratuzumab produced clinically relevant improvements in disease activity in patients…Abstract Number: 1739 • 2013 ACR/ARHP Annual Meeting
Sustained British Isles Lupus Assessment Group-Measured Improvement In Moderately-and-Severely Affected Body Systems In Patients With Systemic Lupus Erythematosus By Epratuzumab: Results From An Open-Label Extension Study
Background/Purpose: Epratuzumab is a monoclonal antibody targeting CD22. In EMBLEMTM (a dose-ranging phase IIb study), epratuzumab produced clinically relevant improvements in disease activity in patients…Abstract Number: 1573 • 2013 ACR/ARHP Annual Meeting
Longer Duration Of B Cell Depletion In Patients With Systemic Lupus Erythematosus Is Associated With a Better Outcome
Background/Purpose: We were alerted to the possibility of very long term B cell depletion (BCD) in Systemic Lupus Erythematosus (SLE) by a patient treated with…Abstract Number: 2542 • 2013 ACR/ARHP Annual Meeting
Validation Of The Revised Selena Flare Index In Systemic Lupus Erythematosus
Background/Purpose: The SELENA flare index (SFI) has been used in clinical and clinical trial settings since 2005 (1), but has the limitation that it classifies…Abstract Number: 2548 • 2013 ACR/ARHP Annual Meeting
Assessment Of Worsening In Lupus Clinical Trials: Do The Endpoints Reflect Medical Judgement?
Background/Purpose: Discrimination between treatment and placebo is problematic in lupus trials. Recently, composite endpoints have evolved which define response by both improvement in baseline findings…Abstract Number: 2621 • 2012 ACR/ARHP Annual Meeting
Sustained Disease Improvement and Safety Profile Over 1745 Patient-Year Experience (7 years) with Belimumab in Systemic Lupus Erythematosus Patients
Background/Purpose: To update belimumab safety and efficacy data over 7 y in patients with active SLE. Methods: 449 SLE patients with SELENA-SLEDAI scores ≥4 were enrolled…
ACR Meeting Abstracts